Serotonin and the extrapyramidal system - A neurological perspective

Human Psychopharmacology

Volumn 11, Issue SUPPL. 2, 1996, Pages

  Meara, Jolyon ^a  

^a GLAN CLWYD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; AMFEBUTAMONE; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FENFLURAMINE; IMIPRAMINE; LEVODOPA; NEUROLEPTIC AGENT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRYPTOPHAN;

BASAL GANGLION; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CORPUS STRIATUM; DEPRESSION; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYSTEM; HUMAN; HUNTINGTON CHOREA; NEUROLOGIC DISEASE; OBSESSION; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SEROTONINERGIC SYSTEM;

EID: 0029789759     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-1077(199606)11:2+3.0.CO;2-C     Document Type: Review

References (68)

1. Alexander, G. E., DeLong, M. R. and Strick, P. L. (1986). Parallel organisation of functionally segregated circuits linking basal ganglia and cortex. Annual Review Neuroscience, 9, 357-381.
2. Andersen, G., Vestergaard, K. and Riis, J. O. (1993). Citalopram for post-stroke crying. Lancet, 342, 837-839.
3. Andersen, G., Vestergaard, K. and Lauritzen, L. (1994). Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor citalopram. Stroke, 25, 6, 1099-1104.
4. Andersen, J., Aabro, E., Gulmann, N., Hjelmsted, A. and Pedersen, H. E. (1980) Anti-depressive treatment in Parkinson's disease: a controlled trail of the effect of nortriptyline in patients with Parkinson's disease treated with L-dopa. Acta Neurologica Scandinavica, 62, 210-219.
5. Arevalo, G. J. G. and Gershanik, O. S. (1993). Modulatory effect on levodopa response in Parkinson's disease: a preliminary study. Movement Disorders, 8, 349-354.
6. Auff, E., Birkmeyer, W., Brucke, T., Deecke, L., Emich, C., Goldenberg, G., Hirsch, E., Maly, J., Muller, C., Potzl, G., Riederer, P., Sofic, E. and Schnaberth, G. (1987). Ritanserin in the treatment of tremor-dominant Parkinson's disease: a preliminary study. New Trends in Clinical Neuropharmacology, 1, 3, 149-158.
7. Baldessarini, R. J. and Marsh, E. (1990). Fluoxetine and side effects. Archives of General Psychiatry, 47, 191-192.
8. Bennett, J. P., Landow, E. R. and Schuh, L. A. (1993). Suppression of dykinesias in advanced Parkinson's disease. Neurology, 43, 1551-1555.
9. Berk, M. (1993). Paroxetine induces dystonia and parkinsonism in obsessive compulsive disorder. Human Psychopharmacology, 8, 444-445.
10. 3 receptor releases dopamine from rat striatal slices. European Journal of Pharmacology, 155, 349-350.
11. Bouchard, R. H., Pourcher, E. and Vincent, P. (1989). Fluoxetine and extrapyramidal side effects. American Journal of Psychiatry, 146, 1352-1353.
12. Caine, E. D., Polinsky R. J., Kartzinel, R. and Ebert, M. H. (1979). The trial use of clozapine for abnormal involuntary movement disorders. American Journal of Psychiatry, 136, 317-320.
13. Caley, C. F. and Friedman, J. H. (1992). Does fluoxetine exacerbate Parkinson's disease? Journal of Clinical Psychiatry, 53, 278-282.
14. Caligiuri, M. P., Lohr, J. B. and Jeste, D. V. (1993). Parkinsonism in neuroleptic-naive schizophrenic patients. American Journal of Psychiatry, 150, 1343-1348.
15. Chase, T. N., Ng, L. K. Y. and Watanabe, A. N. (1972). Parkinson's disease modification by 5-hydroxytryptophan. Neurology, 22, 479-484.
16. Chouinard, G. and Sultan, S. (1992). A case of Parkinson's disease exacerbated by fluoxetine. Human Psychopharmacology, 7, 63-66.
17. Coppen, A., Metcalfe, M., Carroll, J. D. and Morris, J. G. (1972). Levodopa and L-tryptophan therapy in Parkinsonism. Lancet, i, 654-658.
18. Costall, B., Naylor, R. J., Marsden, C. E. and Pycock, C. J. (1976). Serotonergic modulation of the dopamine responses from the nucleus accumbens. Journal of Pharmacy and Pharmacology, 28, 523-526.
19. Coward, D. M. (1992). General pharmacology of clozapine. British Journal of Psychiatry, 160 (suppl. 17), 5-11.
20. Cummings, J. L. (1992). Depression and Parkinson's disease: a review. American Journal of Psychiatry, 149, 443-454.
21. Cummings, J. L. and Cunningham, K. (1992). Obsessive-compulsive disorder in Hungtington's disease. Biological Psychiatry, 31, 263-270.
22. Danielzyck, W. (1992). Mental disorders in Parkinson's disease. Journal of Neural Transmission, Suppl. 38, 115-127.
23. D'Amato, R. J., Zweig, R. M., Whitehouse, P. J., Wenk, G. L., Singer, H. S., Mayeux, R., Price, D. L. and Snyder, S. H. (1987). Aminergic systems in Alzheimer's disease and Parkinson's disease. Annals of Neurology, 22, 229-236.
24. Dooneief, G., Mirabello, E., Bell, K., Marder, K., Stern, Y. and Mayeux, R. (1992). An estimate of the incident of depression in idiopathic Parkinson's disease. Archives of Neurology, 49, 305-307.
25. Dray, A. (1981). Serotonin in the basal ganglia: functions and interactions with other neuronal pathways. Journal of Physiology, Paris, 77, 393-403.
26. Drescher, C. T. and Hetey, L. (1988). Influence of antipsychotics and serotonin antagonists on presynaptic receptors modulating the release of serotonin in synaptosomes of the nucleus accumbens of rats. Neuropharmacology, 27, 31-36.
27. Fischer, P. A., Baas, H. and Hefner, R. (1990). Treatment of parkinsonian tremor with clozapine. Journal Neural Transmission, 2, 223-238.
28. Flemiger, S. (1991). Left-sided Parkinson's disease is associated with greater anxiety and depression. Psychological Medicine, 21, 629-638.
29. Fontes Ribeiro, C. A. (1991). Pharmacology of serotonin neuronal systems. Human Psychopharmacology, 6, S37-51.
30. Goetz, G. G., Tanner, C. M. and Klawans, H.L. (1984). Bupropion in Parkinson's disease. Neurology, 34, 1092-1094.
31. Gotham, A. M., Brown, R. G. and Marsden, C. D. (1986). Depression in Parkinson's disease: a quantitative and qualitative analysis. Journal of Neurology, Neurosurgery and Psychiatry, 49, 381-389.
32. House, A., Dennis, M., Molyneux, A., Warlow, C. and Hawton, K. (1989). Emotionalism after stroke. British Medical Journal, 298, 991-994.
33. House, A., Dennis, M., Warlow, C., Hawton, K. and Molyneux, A. (1990). Mood disorders after stroke and their relation to lesion location. Brain, 113, 1113-1129.
34. House, A., Dennis, M., Mogridge, L., Warlow, C., Hawton, K. and Jones, L. (1991). Mood disorders in the year after first stroke. British Journal of Psychiatry, 158, 83-92.
35. Hildebrand, J. and Delecluse, F. (1987). Effect of ritanserin, a selective serotonin-S2 antagonist, on parkinsonian rest tremor. Current Therapeutic Research, 41, 2, 298-300.
36. Hughes, A. J., Daniel, S. E. Kilford, L. and Lees, A. J. (1992). Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery and Psychiatry, 55, 181-184.
37. Jellinger, K. (1986). Overview of morphological changes in Parkinson's disease, In: Advances in Neurology: Parkinson's Disease, Yahr, M. D. and Bergmann, K. J. (Eds), Raven Press, New York, pp. 1-19.
38. Kahn, N., Freeman, A., Juncos, J. L., Manning, D. and Watts, R. L. (1991). Clozapine is beneficial for psychosis in Parkinson's disease. Neurology, 41, 1699-1700.
39. Karstaedt, P. J., Kerasidis, H., Pincus J. H., Meloni, R., Graham, J. and Gale, K. (1994). Unilateral destruction of dopamine pathways increase ipsilateral striatal serotonin turnover in rats. Experimental Neurology, 126, 25-30.
40. Korsgaard, S., Noring, U., Povlsen, U. J. and Gerlach, J. (1986). Effects of citalopram, a specific serotonin uptake inhibitor, in tardive dyskinesia and Parkinsonism. Clinical Neuropharmacology, 9, 52-57.
41. Kostic, V. S., Djuricic, B. M., Covickovic-Sternis, N., Bumbasirevic, L., Nikolic, M. and Mrsulja, B. B. (1987). Depression and Parkinson's disease: possible role of serotonergic mechanisms. Journal of Neurology, 234, 94-96.
42. Kostic, V. S., Lecic, D., Filipovic, S. and Sternic, N. (1993). Prolactin and cortisol responses to fenfluramine in depressed parkinsonians: diminished responsivity of central serotonergic function. Abstract. European Congress on Mental Dysfunction in Parkinson's Disease, IV-8, 42.
43. Kunovac, J. L. and Stahl, S. M. (1995). Biochemical pharmacology of serotonin receptor subtypes: hypotheses for clinical applications of selective sertonin ligands. International Review of Psychiatry, 7, 55-67.
44. Laitinen, L. (1969). Desipramine in treatment of Parkinson's disease. Acta Neurological Scandinavica, 45, 109-113.
45. Leonard, B. E. (1995). Biological markers of serotonin receptors in depression and animal models of depression. International Review of Psychiatry, 7, 69-84.
46. Marsden C. A. (1991). The neuropharmacology of serotonin in the central nervous system. In: Selective Serotonin Re-uptake Inhibitors. Perspectives in Psychiatry Vol. 1, Feighner. J. P. and Boyer, W. (Eds), John Wiley, Chichester, pp. 11-35.
47. Mayeux, R., Stern Y., Cote, L. and Williams, J. B. W. (1984). Altered serotonin metabolism in depressed patients with Parkinson's diseases. Neurology, 34, 642-646.
48. Mayeux, R., Stern Y., Sano, M., Williams, J. B. W. and Cote, L. (1988). The relationship of serotonin to depression in Parkinson's disease. Movement Disorders, 3, 237-244.
49. McCance-Katz, E. F., Marek, K. L. and Price, L. H. (1992). Serotonergic dysfunction in depression associated with Parkinson's disease. Neurology, 42, 1813-1814.
50. Meara, R. J., Bhowmick, B. K. and Hobson, J. P. (1996). An open uncontrolled study of the use of sertraline in the treatment of depression in Parkinson's disease. Journal of Serotonin Research, in press.
51. Meco, G., Marini, S., Lestingi, L., Linfante, I., Modarelli, F. T. and Agnoli, A. (1988). Controlled single-blind crossover study of ritanserin and placebo in L-dopa-induced dyskinesias in Parkinson's disease. Current Therapeutic Research, 43, 2, 262-270.
52. Meco, G., Bonifati, V., Fabrizio, E. and Vanacore, N. (1994). Worsening of Parkinsonism with fluvoxamine - two cases. Human Psychopharmacology, 9, 439-441.
53. Meltzer, H. Y. (1994). An overview of the mechanism of action of clozapine. Journal Clinical Psychiatry, 55, 9(Suppl. B), 47-52.
54. Meltzer, H. Y., Young, M., Metz, J., Fang, V. S., Schyue, P. M. and Arora, R. C. (1979). Extrapyramidal side-effects and increased serum prolactin following fluoxetine, a new antidepressant. Journal of Neural Transmission, 45, 165-175.
55. Muramatsu, M., Tamaki-Ohashi, J., Usuki, C., Araki, H., Chaki, S. and Aihara, H. (1988). 5-HT2 antagonists and minaprine block the 5-HT-induced inhibition of dopamine release from rat brain striatal slices. European Journal of Pharmacology, 153, 89-95.
56. Peyser, C. E. and Folstein, S. E. (1990). Huntington's disease as a model for mood disorders: clues from neuropathology and neurochemistry. Molecular Chemical Neuropathology, 12, 2, 99-119.
57. 3H-paroxetine binding sites in putamen. Neurology, 36, 556-560.
58. Robinson, R. G., Kubos, K. L., Starr, L. B., Rao, K. and Price, T. R. (1984). Mood disorders in stroke patients: importance of location of lesion. Brain, 107, 81-93.
59. Sajatovic, M., Verbanac, P., Ramirez, L. F. and Meltzer, H. Y. (1991). Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea. Neurology, 41, 156.
60. Schneider, L. S., Chui, H. C., Severson, J. A. and Sloane, R. B. (1988). Decreased platelet binding in Parkinson's disease. Biological Psychiatry, 24, 348-351.
61. Scholz, E. and Dichgans, J. (1985). Treatment of drug-induced exogenous psychosis in Parkinsonism with clozapine and fluperlapine. European Archives of Psychiatric and Neurological Science, 23 S, 60-64.
62. Shihabuddin, L. and Rapport, D. (1994). Sertraline and extrapyramidal effects. American Journal of Psychiatry, 151, 2, 288.
63. Starkstein, S. E. and Robinson, R. G. (1991). Dementia of depression in Parkinson's disease and stroke. Journal of Nervous and Mental Diseases, 179, 593-601.
64. Steur, E. N. H. J. (1993). Increase of Parkinsonian disability after fluoxetine medication. Neurology, 43, 211-213.
65. Strang, R. R. (1965). Imipramine in treatment of parkinsonism: a double-blind placebo study. British Medical Journal, 2, 33-34.
66. Tricklebank, M. D. (1989). Interactions between dopamine and 5-HT3 receptors suggest new treatments for psychosis and drug addiction. Trends in Pharmacological Science, 10, 127-129.
67. Wolters, E, C., Hurwitz, T. A., Mak, E., Teal, P., Peppard, F. R., Remick, R., Caine, S. and Calne, D. B. (1990). Clozapine in the treatment of dopaminomimetic psychosis. Neurology, 40, 832-834.
68. Yakolev, P. I. and Lecours. A-R. (1967). The myelogenetic cycles of the regional maturation of the brain. In: Regional Development of the Brain in Early Life, Minkowski, A. (Ed.), Blackwell Scientific, Oxford, pp. 3-65.